Literature DB >> 33392098

Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.

Yinkui Wang1, Zining Liu1, Fei Shan1, Xiangji Ying1, Yan Zhang1, Shuangxi Li1, Yongning Jia1, Ziyu Li1, Jiafu Ji1.   

Abstract

BACKGROUND: The relationship between time to surgery (TTS) and survival benefit is not sufficiently demonstrated by previous studies in locally advanced gastric cancer (LAGC). This study aims to assess the impact of TTS after neoadjuvant chemotherapy (NACT) on long-term and short-term outcomes in LAGC patients.
METHODS: Data were collected from patients with LAGC who underwent NACT between January 2007 and January 2018 at our institution. Outcomes assessed were long-term survival, pathologic complete response (pCR) rate, and postoperative complications.
RESULTS: This cohort of 426 patients was divided into five groups by weeks of TTS. Under cox regression, compared to other groups, the 22-28 days and 29-35 days groups revealed a better OS (≤21 vs. 22-28 days: HR 1.54, 95% CI = 0.81-2.93, P = 0.185; 36-42 vs. 22-28 days: HR 2.20, 95% CI = 1.28-3.79, P = 0.004; 43-84 vs. 22-28 days: HR 1.83, 95% CI = 1.09-3.06, P = 0.022) and PFS (≤21 vs. 22-28 days: HR 1.54, 95% CI = 0.81-2.93, P = 0.256; 36-42 vs. 22-28 days: HR 2.20, 95% CI = 1.28-3.79, P = 0.111; 43-84 vs. 22-28 days: HR 1.83, 95% CI = 1.09-3.06, P = 0.047). Further analysis revealed a better prognosis in patients with TTS within 22-35 days (OS: HR 1.78 95% CI = 1.25-2.54, P = 0.001; PFS: HR 1.49, 95% CI = 1.07-2.08, P = 0.017). Postoperative stay was significantly higher in the ≤21 days group, while other parameters revealed no statistical significance (P > 0.05). Restricted cubic spline depicted the nonlinear relationship between TTS and OS/PFS.
CONCLUSION: Patients who received surgery within 3-5 weeks experienced the maximal survival benefit without an increase in postoperative complications or lowering the rate of pCR. Further investigations are warranted.
Copyright © 2020 Wang, Liu, Shan, Ying, Zhang, Li, Jia, Li and Ji.

Entities:  

Keywords:  gastric cancer; neoadjuvant chemotherapy; restricted cubic spline; survival; time to surgery

Year:  2020        PMID: 33392098      PMCID: PMC7773852          DOI: 10.3389/fonc.2020.613988

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  52 in total

1.  Impact of interval timing to surgery on tumor response after neoadjuvant treatment for gastric cancer.

Authors:  Juan Ocaña Jiménez; Pablo Priego; Marta Cuadrado; Luis Alberto Blázquez; Silvia Sánchez Picot; Paula Pastor Peinado; Federico Longo; Fernando López; María Alejandra Caminoa-Lizarralde; Julio Galindo
Journal:  Rev Esp Enferm Dig       Date:  2020-08       Impact factor: 2.086

2.  Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer?

Authors:  Anna Lee; Andrew T Wong; David Schwartz; Joseph P Weiner; Virginia W Osborn; David Schreiber
Journal:  Ann Thorac Surg       Date:  2016-05-04       Impact factor: 4.330

3.  A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Authors:  T N Walsh; N Noonan; D Hollywood; A Kelly; N Keeling; T P Hennessy
Journal:  N Engl J Med       Date:  1996-08-15       Impact factor: 91.245

4.  Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Jaffer A Ajani; Thomas A D'Amico; Khaldoun Almhanna; David J Bentrem; Joseph Chao; Prajnan Das; Crystal S Denlinger; Paul Fanta; Farhood Farjah; Charles S Fuchs; Hans Gerdes; Michael Gibson; Robert E Glasgow; James A Hayman; Steven Hochwald; Wayne L Hofstetter; David H Ilson; Dawn Jaroszewski; Kimberly L Johung; Rajesh N Keswani; Lawrence R Kleinberg; W Michael Korn; Stephen Leong; Catherine Linn; A Craig Lockhart; Quan P Ly; Mary F Mulcahy; Mark B Orringer; Kyle A Perry; George A Poultsides; Walter J Scott; Vivian E Strong; Mary Kay Washington; Benny Weksler; Christopher G Willett; Cameron D Wright; Debra Zelman; Nicole McMillian; Hema Sundar
Journal:  J Natl Compr Canc Netw       Date:  2016-10       Impact factor: 11.908

5.  Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer.

Authors:  Zi-Yu Li; Fei Shan; Lian-Hai Zhang; Zhao-De Bu; Ai-Wen Wu; Xiao-Jiang Wu; Xiang-Long Zong; Qi Wu; Hui Ren; Jia-Fu Ji
Journal:  World J Surg Oncol       Date:  2011-09-26       Impact factor: 2.754

6.  Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy.

Authors:  Bo Hultman; Haile Mahteme; Magnus Sundbom; Martin Ljungman; Rolf Larsson; Peter Nygren
Journal:  J Exp Clin Cancer Res       Date:  2014-12-21

Review 7.  Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches.

Authors:  Margherita Ratti; Andrea Lampis; Jens C Hahne; Rodolfo Passalacqua; Nicola Valeri
Journal:  Cell Mol Life Sci       Date:  2018-09-01       Impact factor: 9.261

8.  Management of Cancer Surgery Cases During the COVID-19 Pandemic: Considerations.

Authors:  David L Bartlett; James R Howe; George Chang; Aimee Crago; Melissa Hogg; Giorgos Karakousis; Edward Levine; Ajay Maker; Eleftherios Mamounas; Kandace McGuire; Nipun Merchant; David Shibata; Vance Sohn; Carmen Solorzano; Kiran Turaga; Richard White; Anthony Yang; Sam Yoon
Journal:  Ann Surg Oncol       Date:  2020-04-08       Impact factor: 5.344

9.  Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes.

Authors:  Yi Liu; Ke-Cheng Zhang; Xiao-Hui Huang; Hong-Qing Xi; Yun-He Gao; Wen-Quan Liang; Xin-Xin Wang; Lin Chen
Journal:  World J Gastroenterol       Date:  2018-01-14       Impact factor: 5.742

10.  Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer.

Authors:  Shen-Bao Hu; Chun-Hao Liu; Xiang Wang; Yun-Wei Dong; Lin Zhao; Hong-Feng Liu; Yue Cao; Ding-Rong Zhong; Wei Liu; Yan-Long Li; Wei-Sheng Gao; Chun-Mei Bai; Zhong-Hua Shang; Xiao-Yi Li
Journal:  World J Surg Oncol       Date:  2019-01-03       Impact factor: 2.754

View more
  5 in total

1.  The Effect of Delayed Oncology Surgery on Survival Outcomes for Patients With Gastric Cancer During the COVID-19 Pandemic: Evidence-Based Strategies.

Authors:  Jichun Ma; Chenglou Zhu; Weidong Li; Zhisheng Qiu; Jian Yang; Long Ge; Mingxu Da
Journal:  Front Oncol       Date:  2022-05-19       Impact factor: 5.738

2.  Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A "Less Is More" Question When ypN0 Is Achieved.

Authors:  Zining Liu; Yinkui Wang; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Rulin Miao; Kan Xue; Zhemin Li; Ziyu Li; Jiafu Ji
Journal:  Front Oncol       Date:  2021-12-01       Impact factor: 6.244

3.  Current status and future perspectives on neoadjuvant therapy in gastric cancer.

Authors:  Sheng Ao; Yuchen Wang; Qingzhi Song; Yingjiang Ye; Guoqing Lyu
Journal:  Chin J Cancer Res       Date:  2021-04-30       Impact factor: 5.087

4.  Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer.

Authors:  Pengjie Yu; Shengmao Zhu; Yushuang Luo; Ganggang Li; Yongqiang Pu; Baojia Cai; Chengwu Zhang
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

5.  Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.

Authors:  Zining Liu; Yinkui Wang; Fei Shan; Xiangji Ying; Yan Zhang; Shuangxi Li; Yongning Jia; Rulin Miao; Kan Xue; Zhemin Li; Ziyu Li; Jiafu Ji
Journal:  Ann Surg Oncol       Date:  2021-07-29       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.